Identification of the risks in CAR T-cell therapy clinical trials in China: a Delphi study

Aims: Within the past few years, there has been tremendous growth in clinical trials of chimeric antigen receptor (CAR) T-cell therapies. Unlike those of many small-molecule pharmaceuticals, CAR T-cell therapy clinical trials are fraught with risks due to the use of live cell products. The aim of th...

Full description

Bibliographic Details
Main Authors: Weijia Wu, Yan Huo, Xueying Ding, Yuhong Zhou, Shengying Gu, Yuan Gao
Format: Article
Language:English
Published: SAGE Publishing 2020-10-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758835920966574

Similar Items